Sanofi (SNYNF)
USD 98.65
(0.0%)
USD 98.65
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 26.49 Billion EUR | -16.39% |
| 2022 | 31.69 Billion EUR | 17.73% |
| 2021 | 26.92 Billion EUR | 6.77% |
| 2020 | 25.21 Billion EUR | -1.73% |
| 2019 | 25.65 Billion EUR | 5.83% |
| 2018 | 24.24 Billion EUR | -1.43% |
| 2017 | 24.59 Billion EUR | 2.45% |
| 2016 | 24 Billion EUR | 0.27% |
| 2015 | 23.94 Billion EUR | 3.73% |
| 2014 | 23.08 Billion EUR | 3.42% |
| 2013 | 22.31 Billion EUR | -10.16% |
| 2012 | 24.83 Billion EUR | 2.83% |
| 2011 | 24.15 Billion EUR | 3.59% |
| 2010 | 23.31 Billion EUR | 1.96% |
| 2009 | 22.86 Billion EUR | 6.46% |
| 2008 | 21.48 Billion EUR | -0.87% |
| 2007 | 21.67 Billion EUR | -1.06% |
| 2006 | 21.9 Billion EUR | 4.64% |
| 2005 | 20.93 Billion EUR | 85.54% |
| 2004 | 11.28 Billion EUR | 70.7% |
| 2003 | 6.6 Billion EUR | 8.77% |
| 2002 | 6.07 Billion EUR | 16.07% |
| 2001 | 5.23 Billion EUR | 15.79% |
| 2000 | 4.52 Billion EUR | 17.19% |
| 1999 | 3.85 Billion EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 10.07 Billion EUR | -24.17% |
| 2024 Q1 | 7.67 Billion EUR | -44.44% |
| 2024 Q2 | 13.28 Billion EUR | 72.97% |
| 2023 Q3 | 8.85 Billion EUR | 19.46% |
| 2023 Q4 | 13.82 Billion EUR | 56.03% |
| 2023 Q1 | 7.78 Billion EUR | 0.8% |
| 2023 FY | 26.49 Billion EUR | -16.39% |
| 2023 Q2 | 7.41 Billion EUR | -4.75% |
| 2022 Q1 | 7.17 Billion EUR | 3.36% |
| 2022 Q2 | 7.49 Billion EUR | 4.45% |
| 2022 Q3 | 9.3 Billion EUR | 24.23% |
| 2022 Q4 | 7.72 Billion EUR | -17.03% |
| 2022 FY | 31.69 Billion EUR | 17.73% |
| 2021 Q2 | 6.18 Billion EUR | -0.23% |
| 2021 Q3 | 7.59 Billion EUR | 22.67% |
| 2021 Q4 | 6.94 Billion EUR | -8.58% |
| 2021 FY | 26.92 Billion EUR | 6.77% |
| 2021 Q1 | 6.2 Billion EUR | -1.52% |
| 2020 Q1 | 6.45 Billion EUR | -1.66% |
| 2020 Q2 | 5.76 Billion EUR | -10.71% |
| 2020 Q3 | 6.7 Billion EUR | 16.37% |
| 2020 FY | 25.21 Billion EUR | -1.73% |
| 2020 Q4 | 6.29 Billion EUR | -6.04% |
| 2019 Q2 | 6.21 Billion EUR | 1.94% |
| 2019 Q1 | 6.09 Billion EUR | -1.5% |
| 2019 FY | 25.65 Billion EUR | 5.83% |
| 2019 Q4 | 6.56 Billion EUR | -3.34% |
| 2019 Q3 | 6.78 Billion EUR | 9.24% |
| 2018 Q1 | 5.58 Billion EUR | -5.29% |
| 2018 Q2 | 5.76 Billion EUR | 3.23% |
| 2018 Q3 | 6.71 Billion EUR | 16.51% |
| 2018 Q4 | 6.18 Billion EUR | -7.81% |
| 2018 FY | 24.24 Billion EUR | -1.43% |
| 2017 Q1 | 6.11 Billion EUR | -1.75% |
| 2017 Q3 | 6.54 Billion EUR | 8.13% |
| 2017 Q4 | 5.89 Billion EUR | -9.89% |
| 2017 FY | 24.59 Billion EUR | 2.45% |
| 2017 Q2 | 6.04 Billion EUR | -1.05% |
| 2016 FY | 24 Billion EUR | 0.27% |
| 2016 Q2 | 5.78 Billion EUR | 5.55% |
| 2016 Q1 | 5.48 Billion EUR | -7.93% |
| 2016 Q4 | 6.22 Billion EUR | -4.57% |
| 2016 Q3 | 6.51 Billion EUR | 12.69% |
| 2015 Q3 | 6.68 Billion EUR | 2.44% |
| 2015 FY | 23.94 Billion EUR | 3.73% |
| 2015 Q1 | 6.1 Billion EUR | -0.41% |
| 2015 Q4 | 5.95 Billion EUR | -10.91% |
| 2015 Q2 | 6.52 Billion EUR | 6.86% |
| 2014 Q2 | 5.53 Billion EUR | 2.38% |
| 2014 Q1 | 5.4 Billion EUR | -4.15% |
| 2014 FY | 23.08 Billion EUR | 3.42% |
| 2014 Q3 | 6 Billion EUR | 8.41% |
| 2014 Q4 | 6.12 Billion EUR | 2.08% |
| 2013 Q2 | 5.41 Billion EUR | -3.65% |
| 2013 Q1 | 5.61 Billion EUR | -2.95% |
| 2013 FY | 22.31 Billion EUR | -10.16% |
| 2013 Q4 | 5.64 Billion EUR | -0.02% |
| 2013 Q3 | 5.64 Billion EUR | 4.27% |
| 2012 Q4 | 5.78 Billion EUR | -8.98% |
| 2012 FY | 24.83 Billion EUR | 2.83% |
| 2012 Q1 | 6.31 Billion EUR | 2.94% |
| 2012 Q3 | 6.36 Billion EUR | -0.45% |
| 2012 Q2 | 6.38 Billion EUR | 1.25% |
| 2011 FY | 24.15 Billion EUR | 3.59% |
| 2011 Q4 | 6.13 Billion EUR | -2.34% |
| 2011 Q1 | 5.82 Billion EUR | 6.08% |
| 2011 Q2 | 5.92 Billion EUR | 1.6% |
| 2011 Q3 | 6.27 Billion EUR | 6.01% |
| 2010 Q3 | 5.96 Billion EUR | -2.52% |
| 2010 FY | 23.31 Billion EUR | 1.96% |
| 2010 Q4 | 5.49 Billion EUR | -7.87% |
| 2010 Q2 | 6.11 Billion EUR | 6.49% |
| 2010 Q1 | 5.74 Billion EUR | 4.51% |
| 2009 Q1 | 5.68 Billion EUR | 2.84% |
| 2009 FY | 22.86 Billion EUR | 6.46% |
| 2009 Q4 | 5.49 Billion EUR | -4.32% |
| 2009 Q3 | 5.74 Billion EUR | -3.38% |
| 2009 Q2 | 5.94 Billion EUR | 4.59% |
| 2008 Q1 | 5.33 Billion EUR | -34.68% |
| 2008 FY | 21.48 Billion EUR | -0.87% |
| 2008 Q4 | 5.52 Billion EUR | 2.89% |
| 2008 Q3 | 5.37 Billion EUR | 1.44% |
| 2008 Q2 | 5.29 Billion EUR | -0.68% |
| 2007 FY | 21.67 Billion EUR | -1.06% |
| 2007 Q3 | 6.96 Billion EUR | 27.22% |
| 2007 Q2 | 5.47 Billion EUR | -22.35% |
| 2007 Q1 | 7.05 Billion EUR | -4.47% |
| 2007 Q4 | 8.16 Billion EUR | 17.12% |
| 2006 Q2 | 5.54 Billion EUR | 1.83% |
| 2006 FY | 21.9 Billion EUR | 4.64% |
| 2006 Q1 | 5.44 Billion EUR | 0.15% |
| 2006 Q4 | 7.38 Billion EUR | 0.42% |
| 2006 Q3 | 7.35 Billion EUR | 32.58% |
| 2005 Q2 | 4.97 Billion EUR | 0.19% |
| 2005 Q4 | 5.44 Billion EUR | -1.8% |
| 2005 Q3 | 5.53 Billion EUR | 11.46% |
| 2005 Q1 | 4.96 Billion EUR | -6.85% |
| 2005 FY | 20.93 Billion EUR | 85.54% |
| 2004 Q1 | 2.22 Billion EUR | 25.71% |
| 2004 FY | 11.28 Billion EUR | 70.7% |
| 2004 Q3 | 5.33 Billion EUR | 191.81% |
| 2004 Q2 | 1.82 Billion EUR | -17.91% |
| 2004 Q4 | 5.32 Billion EUR | -0.17% |
| 2003 Q1 | 1.94 Billion EUR | 3.09% |
| 2003 Q2 | 1.57 Billion EUR | -19.16% |
| 2003 Q3 | 2.41 Billion EUR | 53.67% |
| 2003 Q4 | 1.77 Billion EUR | -26.71% |
| 2003 FY | 6.6 Billion EUR | 8.77% |
| 2002 Q3 | 1.87 Billion EUR | 26.04% |
| 2002 Q2 | 1.48 Billion EUR | 0.0% |
| 2002 FY | 6.07 Billion EUR | 16.07% |
| 2002 Q4 | 1.88 Billion EUR | 0.86% |
| 2001 FY | 5.23 Billion EUR | 15.79% |
| 2000 FY | 4.52 Billion EUR | 17.19% |
| 1999 FY | 3.85 Billion EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | 23.622% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | 22.776% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | 12.078% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -235710.27% |
| Novartis AG | 34.18 Billion USD | 22.493% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | -3464.083% |